CRL Stock Gets Stronger EPS Estimate from Zacks Research

Charles River Laboratories International, Inc. (NYSE:CRL) – Equities researchers at Zacks Research boosted their Q4 2026 earnings estimates for Charles River Laboratories International in a research report issued to clients and investors on Monday, October 5th. Zacks Research analyst Team now forecasts that the medical research company will post earnings of $3.15 per share for the quarter, up from their previous estimate of $3.13. Zacks Research has a “Strong-Buy” rating on the stock. The consensus estimate for Charles River Laboratories International’s current full-year earnings is $11.36 per share. Zacks Research also issued estimates for Charles River Laboratories International’s Q1 2027 earnings at $2.57 EPS and Q4 2027 earnings at $3.42 EPS.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Wednesday, August 5th. The medical research company reported $3.02 earnings per share for the quarter, beating the consensus estimate of $2.77 by $0.25. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. The company had revenue of $1 billion during the quarter, compared to analyst estimates of $980.53 million. During the same quarter last year, the firm posted $3.12 EPS. The business’s revenue for the quarter was down 2.7% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS.

Other equities analysts have also recently issued reports about the company. Jefferies Financial Group lifted their target price on Charles River Laboratories International from $305.00 to $340.00 and gave the stock a “buy” rating in a report on Monday, September 28th. Sanford C. Bernstein set a $250.00 price target on Charles River Laboratories International in a research report on Wednesday, July 1st. Deutsche Bank Aktiengesellschaft boosted their price objective on Charles River Laboratories International from $300.00 to $320.00 and gave the stock a “buy” rating in a report on Friday, September 25th. Morgan Stanley upped their price objective on shares of Charles River Laboratories International from $260.00 to $300.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. Finally, CLSA downgraded shares of Charles River Laboratories International from an “outperform” rating to a “hold” rating and set a $219.00 target price on the stock. in a research report on Monday, July 20th. Two analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $300.11.

Charles River Laboratories International Price Performance

NYSE CRL opened at $297.64 on Wednesday. Charles River Laboratories International has a 1 year low of $146.20 and a 1 year high of $333.30. The business’s fifty day moving average is $283.03 and its two-hundred day moving average is $222.20. The stock has a market capitalization of $14.21 billion, a P/E ratio of -61.37, a P/E/G ratio of 2.81 and a beta of 1.40. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.04 and a current ratio of 1.35.

Institutional Trading of Charles River Laboratories International

A number of institutional investors have recently bought and sold shares of the company. Empirical Finance LLC raised its position in shares of Charles River Laboratories International by 4.4% in the 2nd quarter. Empirical Finance LLC now owns 1,469 shares of the medical research company’s stock worth $333,000 after acquiring an additional 62 shares in the last quarter. Glenmede Trust Co. NA boosted its position in shares of Charles River Laboratories International by 2.8% during the 1st quarter. Glenmede Trust Co. NA now owns 2,706 shares of the medical research company’s stock valued at $467,000 after purchasing an additional 73 shares in the last quarter. Syon Capital LLC grew its stake in Charles River Laboratories International by 2.4% during the second quarter. Syon Capital LLC now owns 3,547 shares of the medical research company’s stock worth $804,000 after purchasing an additional 83 shares during the period. Brown Miller Wealth Management LLC grew its stake in Charles River Laboratories International by 7.0% during the first quarter. Brown Miller Wealth Management LLC now owns 1,278 shares of the medical research company’s stock worth $220,000 after purchasing an additional 84 shares during the period. Finally, Arizona State Retirement System increased its holdings in Charles River Laboratories International by 0.6% in the second quarter. Arizona State Retirement System now owns 13,615 shares of the medical research company’s stock worth $3,088,000 after purchasing an additional 86 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Insiders Place Their Bets

In related news, Director Nancy C. Andrews sold 573 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $285.24, for a total transaction of $163,442.52. Following the completion of the sale, the director directly owned 1,438 shares in the company, valued at approximately $410,175.12. This trade represents a 28.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director James C. Foster sold 33,561 shares of the company’s stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $300.00, for a total transaction of $10,068,300.00. Following the completion of the transaction, the director owned 31,596 shares in the company, valued at approximately $9,478,800. This represents a 51.51% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 91,971 shares of company stock valued at $26,033,968 over the last ninety days. Insiders own 1.30% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a contract research organization that provides products and services to support pharmaceutical, biotechnology and academic research. The company helps customers discover, develop and manufacture new medicines, vaccines and other healthcare products.

Its offerings include research models and related services, preclinical drug discovery, pharmacology, toxicology, bioanalysis and safety assessment. Charles River also provides laboratory and manufacturing solutions for biologics, cell and gene therapies, microbial testing and other specialized life sciences applications.

Founded in 1947, Charles River Laboratories serves customers worldwide through operations across North America, Europe and Asia.